On February 6, AstraZeneca released its 2024 financial report, covering the entire year.Revenue of $54.073 billion, an increase of 21% year-on-year(Calculated at constant exchange rates CER, the same below), including product sales of US$50.938 billion (+19%). R&D investment reached US$13.583 billion, a year-on-year increase of 25%.Source: AstraZeneca 2024 Earnings PPTFrom a regional perspective, the United States remains AstraZeneca's primary market, with revenue reaching $23.235 billion in 2024 (+22%), while sales revenue from emerging markets amounted to $13.675 billion (+22%).
Among them, it is worth mentioning that,Revenue in China Hits Record High, Reaching $6.413 Billion, an increase of 11% year-on-year, accounting for 12% of total revenue and 48% of emerging markets.
Source:Insight Database Organization
In terms of products, Farxiga (dapagliflozin) secured the top position as AstraZeneca's best-selling drug with revenue of $7.717 billion, followed by Tagrisso (osimertinib) and Imfinzi (durvalumab), which achieved $6.580 billion (+16%) and $4.717 billion (+21%) respectively in 2024, ranking second and third.
CityPerformance on the field is impressive
Tumors, CVRM, and R&I are growing rapidly
AstraZeneca mainly focuses on oncology,CVRM（Cardiovascular, Renal and Metabolic Diseases）, Respiratory and Immunology（R&I），Vaccines and Immunotherapy（V&I）And in the five major disease areas of rare diseases, they contributed $22.353 billion (+24%), $12.517 billion (+20%), and $7.876 billion (+25%) to the company in 2024, respectively.$14.62 billion (+8%),$8.768 billion (+16%) in revenue.Source：AstraZeneca 2024 Earnings Report
Oncology, as AstraZeneca's core business, has shown strong growth momentum, primarily driven by five blockbuster products: Tagrisso (osimertinib), Imfinzi (durvalumab), Calquence (acalabrutinib), Lynparza (olaparib), and Enhertu (trastuzumab deruxtecan).
Source:AstraZeneca 2024 Earnings PPT, the same belowAmong them, the benchmark ADC product Enhertu (trastuzumab deruxtecan) is the most eye-catching. Since its launch in December 2019, it has achieved annual sales of over $3.4 billion in just five years, contributing $1.982 billion in revenue to AstraZeneca. Recently, the second ADC product from AstraZeneca and Daiichi Sankyo's collaboration, Datroway (TROP2 ADC), has successively entered the Japanese and American markets. Whether this product can replicate the glory of Enhertu remains to be seen.Cardiovascular, renal, and metabolic diseases, as well as respiratory and immunology fields, also showed remarkable performance with growth rates of no less than 20%. Specifically, Farxiga (dapagliflozin), which covers three major types of common chronic conditions—type 2 diabetes, chronic kidney disease, and heart failure—achieved sales of $5.963 billion in 2023, surpassing Tagrisso (osimertinib), the top product for three consecutive years, to become AstraZeneca's best-selling product. In 2024, it generated revenue of $7.717 billion.Asthma and Chronic Obstructive Pulmonary Disease Drug Symbicort (Budesonide + Formoterol) Returns to Growth After Two Consecutive Years of Sales Decline, with 2024 Revenue Reaching $2.879 Billion, a Year-on-Year Increase of 25%.AstraZeneca's rare disease business is comparable in size to its respiratory and immunology business. The two C5 monoclonal antibodies, Ultomiris (ravulizumab) and Soliris (eculizumab), collectively generated $6.512 billion in revenue. However, the sales of Soliris (eculizumab) have declined under the pressure from newer competitors. Nevertheless, AstraZeneca’s rare disease portfolio also includes a neurofibromatosis therapy, Koselugo (Selumetinib) Rapid growth (+96%), may fill the gap.
Key Milestones & Pipeline Changes
Revenue to Reach $800 Billion by 2030
In 2025, AstraZeneca will reach the following milestone events, among whichCalquence, Imfinzi, Ultomiris, Truqap, and Datroway are expected to receive regulatory approval in China.
In addition, the financial report shows that AstraZeneca has terminated six clinical studies since Q3 2024, including one Phase I study and five Phase II studies.
AstraZeneca Predicts High Single-Digit Revenue Growth for 2025By 2030, the company will bring at least 20 new molecules to market and achieve a total revenue of $80 billion.Cover Source:Corporate Logo
Disclaimer:This article is for information sharing only,不代表 Insight 立场和观点, and does not recommend or introduce any treatment options. If you have any needs, please consult and contact正规医疗机构.
Editor: Crescent
PR Article Coordination: WeChat insightxb
Submission: WeChat insightxb; Email insight@dxy.cn
Diversified functions, traceable data……
Insight Database Web Version Awaits Your Experience
Click to read the original text,ImmediatelyUnlock！
